Skip to main content
News Archive

Brightstone Venture Capital on overinflated startup valuations – and other advice for life sciences companies

By May 6, 2015May 22nd, 2025No Comments

Brightstone-Venture-Capital-logo

Every venture firm’s looking for many multiples when it comes to returns – but in reality, they expect things to shake out a little differently. Seth DeGroot, a managing partner at boutique Minneapolis investment firm Brightstone Venture Capital, spoke on what the firm’s expectations in potential investment targets – and how startups can avoid pesky problems like, say, overinflated valuations.

{iframe}http://medcitynews.com/2015/05/brightstone-venture-capital-qa/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.